SUMMARY
# Metabolic Pathway-Targeted Therapy in ALS
## Background and Rationale
This groundbreaking clinical trial represents a precision medicine approach to ALS therapy through comprehensive metabolic pathway targeting based on individual patient metabolomic profiles. Recent advances in systems biology have revealed profound metabolic dysregulation in ALS, including disrupted glucose metabolism, altered lipid homeostasis, and impaired mitochondrial bioenergetics. Rather than pursuing a one-size-fits-a
METHODOLOGY NOTES
**Phase 1: Patient Recruitment and Baseline Assessment (Months 1-3)**
• Recruit 180 ALS patients (90 treatment, 90 placebo) meeting revised El Escorial criteria
• Inclusion: Age 18-75, disease duration <2 years, ALSFRS-R score ≥30
• Exclusion: FVC <65%, significant comorbidities, prior riluzole intolerance
• Conduct comprehensive baseline assessments: ALSFRS-R, FVC, grip strength, metabolomics panel
• Obtain blood samples for targeted metabolomics (amino acids, lipids, glucose metabolism)
• Perform MR spectroscopy for brain metabolite quantification
**Phase 2: Metabolic Pathway Analysis and Stratification (Month 4)**
• Analyze baseline metabolomics data using LC-MS/MS and GC-MS platforms
• Identify dysregulated pathways: glutamate metabolism, mitochondrial function, lipid oxidation
• Stratify patients based on metabolic phenotypes using unsupervised clustering
• Randomize within strata to treatment (metabolic cocktail) vs placebo groups
**Phase 3: Treatment Administration (Months 5-1